Value through Innovation15 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

25.11.2013

Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do not change the position of Pradaxa®

- For media outside of the US, the UK & Canada only
19.11.2013

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

- For media outside of the US, the UK & Canada only
19.11.2013

Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations

- For media outside of the US, the UK & Canada only
18.11.2013

First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation

- For media outside of the US, the UK & Canada only
15.11.2013

Boehringer Ingelheim goes "Blue" in supporting World Diabetes Day activities

13.11.2013

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

- For Media outside the U.S., Canada and UK
12.11.2013

Boehringer Ingelheim supports victims of typhoon Haiyan in the Philippines


12.11.2013

New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013

- For media outside of the US, the UK & Canada only
11.11.2013

Micardis crosses 50 million patient-years of experience on 15th anniversary

- For NON-US and NON-UK Healthcare Media Only
07.11.2013

New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations

- For Non-US and Non-UK Media
06.11.2013

New survey in four major Asian countries reveals complexity of managing Type 2 Diabetes is currently underestimated1

- Ex-US & Ex- UK Medical Media Only
02.11.2013

Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C

- For media outside of the U.S.A., UK and Canada only
02.11.2013

Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data

- For media outside of the U.S.A., UK and Canada only
29.10.2013

New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD1

- For media outside the UK, U.S. and Canada
28.10.2013

Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim

27.10.2013

New efficacy and safety data adds to evidence supporting treatment with afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients

- For NON-US media only
18.10.2013

New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries

- For media outside the UK, U.S. and Canada
14.10.2013

Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval

- For non U.S. Media Only